Kadian for Chronic Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WILMINGTON, Del--Zeneca Inc. has received FDA clearance to market Kadian (morphine sulfate sustained release) capsules, a new single daily dose sustained-release (SR) morphine formulation, for the management of moderate to severe chronic pain when treatment with an opioid analgesic is indicated for more than a few days.

WILMINGTON, Del--Zeneca Inc. has received FDA clearance to marketKadian (morphine sulfate sustained release) capsules, a new singledaily dose sustained-release (SR) morphine formulation, for themanagement of moderate to severe chronic pain when treatment withan opioid analgesic is indicated for more than a few days.

Kadian is the first oral SR morphine in the US that offers theoption of 24-hour pain control with a single dose, the companysaid.

The largest controlled clinical study of Kadian was conductedin cancer patients with moderate to severe chronic pain at 28US centers.

After stabilization with an immediate-release morphine solution,152 patients were randomized to receive one of three treatments:Kadian once every 24 hours, Kadian every 12 hours, or MS Contin(morphine sulfate controlled-release) every 12 hours.

Kadian once every 24 hours was shown to be as effective as theother two regimens, and there were no significant differencesin side effects.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
4 KOLs are featured in this series.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.